
For Healthy Urinary Tract
Urinary tract infections (UTIs) are some of the most common bacterial infections. An estimated 20 to 50% of women have experienced a urinary tract infection (cystitis) at least once in their lifetime, and many of them suffer from recurring UTIs. In general, UTIs are painful. Women are affected more often because of their anatomy. Pregnancy and impaired vaginal microbiota are associated with the onset of UTIs in women, while aging, catheterisation, and prostate enlargement pre-condition UTIs in men. The most common cause of UTIs is Escherichia coli (Е. coli), which is found in 80% of cases.
Lactoflor UROBiotic+ is 100% natural: A synergetic combination of well-researched herbal extracts (Ursolia® containing an extract of Salvia officinalis, and Exocyan® containing cranberry extract), D-mannose, and a probiotic blend. With its scientifically proven beneficial properties, this combination was created for prevention and to maintain a healthy urinary system in both male and female. Through the use of natural ingredients, Lactoflor UROBiotic+ restores impaired balance and reduces the risk of recurring infection, while boosting the body’s natural protection.

Lactoflor UROBiotic+ is a 100% natural product (free of preservatives and GMO), which is suitable for both male and female. Based on an innovative probiotic blend of Ursolia®, D-mannose, and Exocyan®, this product:
• Provides fast relief upon initial symptoms of discomfort during urination.
• Is suitable for pregnant and breastfeeding women, diabetics, and children aged over 6 years.
• Does not cause resistance after long-term intake.
• Is suitable to take in combination with antibiotics.








Each capsule Lactoflor UROBiotic+ contains:
1. Probiotic blend: a unique selection of special strains (L.acidophilus, L.casei,
B. bifidum, B.infantis, and B.longum) ensures an effective antagonistic effect against E.coli and beneficially conditions the urinary tract, vaginal flora, and immune system.
2. Ursolia® is a standardised extract of Salvia officinalis, high in ursolic acid and oleanolic acid. It has distinctive anti-proliferative, anti-oxidative and anti-microbial effects. Ursolic acid helps reduce urinary tract inflammation associated with E.coli. By inhibiting the activity of inflammatory cytokines, it helps alleviate discomfort and inflammation in the lower urinary tract.
3. Exocyan® - standardised dry cranberry extract, which have an anti-adhesion effect against E.coli and destroys the pathogen-receptor bond. Consequently, pathogenic bacteria fail to bind and are removed through urine.
4. D-mannose is 100% natural monosaccharide which exists in some red berries. Studies have demonstrated that D-mannose is able to remove and evacuate pathogenic bacteria. D-mannose blocks the binding of the uropathogenic bacteria E.coli and supports the process of passing pathogens into urine.
Main
Benefits of UROBiotic+

Antibacterial therapy in acute, uncomplicated cystitis includes mostly antibiotic and uroantiseptic agents. But an increase in drug-resistant E.coli strains at present poses a risk of failure with this antibacterial therapy, as well as risk of more frequent recurrent infection, chronification, or intake of high doses of medication.
Natural products (such as UROBiotic+) which have specific anti-adhesion, anti-inflammatory and bacteriostatic effects on the urinary tract can be used as an appropriate alternative to traditional antibacterial agents, especially against recurring infections. UROBiotic+ helps limit the use of antibacterials and reduce the variety of drug-resistant strains, which present a significant problem for clinical practice and public health.
WHY IS LACTOFLOR UROBiotic+ SO EFFECTIVE?
There is a well-established connection between vaginal microbiota and urinary tract infections. Most microorganisms in vaginal microbiota come from the gastrointestinal tract, and so we should ensure beneficial (good) bacteria to prevail within the intestinal microbiota.
Various scientific studies have demonstrated that the intake of probiotics maintains good immunity and regulates gastrointestinal and vaginal microbiota. These effects, in turn, can prevent urinary tract infections. It has been proven that beneficial bacteria (such as Lactobacillus) also have anti-bacterial effect, curbing the growth E.coli.

PROBIOTIC STRAINS CONTAINED IN LACTOFLOR UROBiotic+:
Lactobacillus acidophilus are part of vaginal microbiota. They disintegrate lactose into lactic acid (producing bacteriocins and creating unfavourable conditions for pathogens), stimulate the immune system, and curb development of infection and allergy.
L. casei boost immunity and acts directly against pathogens (viruses and bacteria).
Bifidobacterium sp, B. bifido, B. infantis and B. Longum stimulate production of anti-inflammatory molecules and boost the immune system. They aid metabolism — by synthesizing amino acids, lactic acid, acetic acid, other short-chain fatty acids, and B-group vitamins—and assist in fermentation of carbohydrates. These bacteria protect against pathogens via production of lactic acid and bacteriocins.
INDICATIONS UROBiotic+:
• Prophylaxis in recurrent urinary tract infections (UTI).• Protection against infection in urolithiasis (kidney stones).
• Protection against infection during and after urinary catheterisation.
• Senile urethritis.
• Asymptomatic bacteriuria.
• Follow-up treatment after acute UTI.
• As concomitant therapy in parallel with antibiotic treatment.
• After urological procedures.
RECOMMENDED DOSE:
Physicians Appraisals
Dr Yordan Popov
Dr Dimitar* Angelov
Zdrave
Integrated Hospital for Active Treatment OOD, Pulmed Hospital, Plovdiv, Bulgaria.
Probiotics are widely and successfully used to treat and prevent most diseases,
especially those of the gastrointestinal tract, including diarrhoea and constipation of various
aetiology, implications resulting from antibiotic treatment, food poisoning, acute intestinal
infections, chronic colitis and enterocolitis, weakened immunity, bad breath, chemotherapy and
radiation therapy implications, as well as other conditions. To this end, probiotics should comply
with these requirements:
• High viability.
• Biological activity.
• Resistance to stomach pH.
• Belong to normal GIT inhabitants.
• Be resistant to antibiotics.
• Ability to suppress the growth of pathogenic bacteria and/or viruses.
• Restore and maintain the balance of gastrointestinal microbiota.
As products containing live microorganisms, probiotics also require specific conditions for storage and use. In order to be effective, probiotics should be taken separately from medication and food, at least 20-30 minutes before or after meals with a sufficient amount of water. ( See American Journal of Internal Medicine, NY, 2011.)
Probiotics and probiotic-based products have now taken their well-deserved place in health care, both as adjunctive therapy with antibiotic treatment and as agents used in treating a number of conditions, including IBS, IBD, polychemotherapy implications, antibiotic-associated diarrhoea syndrome, necrotizing enterocolitis, and travelers’ diarrhoea. These products are also used in the reconvalescent period after infectious and viral gastroenterocolitis. In addition, according to most recent publications, probiotic products aid in eradicating H. pylori (based on the biological principle of competition). .
Probiotics help digestion and aid in eliminating and excreting waste from the body and function in the synthesis of vitamins, as well as the inhibition of pathogenic microorganisms and conditional pathogens. Probiotics also facilitate the elimination of toxins. In general, the small intestine and colon host hundreds of types of bacteria which play an active role in building our self-image and health. Gastrointestinal microbiota is constantly subjected to environmental impact and coordinates the function of the immune and digestive systems. Gastrointestinal microbiota maintains the balance and internal environment in the intestines and suppresses the growth of pathogenic microorganisms and conditional pathogens. When the functioning of the GIT is impaired, the growth of pathogens and conditional pathogens is commonly observed, which leads to motility disorders and dysfunction in the processes of resorption and elimination in the GIT. This is where probiotics come into play—restoring biological equilibrium, as well as the balance of gastrointestinal microbiota. (See UK J of Gastroenterology, L., 2011, ch.4, p.256.)
Probiotics contain various microbiological strains of microorganisms that normally exist in our GIT, including the most common and popular ones: Lactobacillus acidophilus, Bifidobacterium bifidum, Lactobacillus casei, Bifidobacterium longum, Lactobacillus rhamnosus, Bifidobacterium infantis, Streptococcus thermophillus, and Lactobacillus bulgaricus. If used properly and regularly and stored appropriately, probiotics are very efficacious in treating and preventing a number of diseases, mostly gastrointestinal tract disorders. (Journal of Clinical Bacteriology, NY, 2010).
In this context, we would like to share our clinical experience in the administration of probiotics. According to WHO (World Health Organization), irritable bowel syndrome (IBS) accounts for some 40% of the cases in gastroenterologists’ routine practice. (Ann J of Gastroenterology, WHO, Geneva, 2012) Administering probiotics in IBS patients has become an established standard in day-to-day medical practice. According to WHO (Ann J of Bact Deseases, WHO, Geneva, 2012), antibiotic-associated dysbacteriosis and diarrhea syndrome account for 25-28% of functional gastrointestinal disorders.
From 01 June to 01 October 2013, 87 patients with IBS were referred to our clinic. Single probiotic therapy was recommended to 70 patients. During follow-up visits, a clinical effect was reported in 60 patients, such results as improved self-image, discontinued bloating, lack of gas and flatulation, regular physiological rhythm in bowel movements. Double therapy was recommended to 17 patients—6 patients received probiotics and concentrated and standardised extracts (via gelatine capsules), and 11 patients received Simethiconе. A clinical effect (in the above indicators) was observed in 14 patients.
The data presented above support the routine administration of probiotics as a monotherapy and their administration in combination with other drugs influencing gastrointestinal motility and adsorption and evacuation of gas that is produced in larger amounts in specific functional and fermentation-associated GI disorders.
From 01 August to 01 October 2013, 23 patients with antibiotic-associated
dysbacteriosis and diarrhoea syndrome were referred to our clinic. It was concluded that 12 of
these patients had classic antibiotic-associated diarrhoea syndrome, resulting from antibiotic
treatment for pulmonary pathology and upper respiratory tract pathology. These patients were
treated with a probiotic monotherapy. An effect (in the above indicators) was reported in all 12
patients. The remaining 11 patients received combination therapy, including a probiotic product and
Otilonium bromide. A clinical effect (in the above indicators) was observed in 10 of these
patients. The above data convincingly demonstrate the effect of administering probiotic agents in
routine clinical practice.
In patients who were prescribed probiotic products manufactured by Kendy Pharma*
*Да се поправи в БГ текста- Kendy, а не Kandy- има го на 4 места до края на този текст
(Lactoflor Probiotic and Lactoflor BioPlus capsules), the following effects were reported:
1. In the group of 87 patients with IBS, probiotics (manufactured by Kendy Pharma) were prescribed
to 56 patients. An effect was reported in all 56 patients. (Effect means that a response was
observed in at least two of the aforementioned indicators.)
2. In the group of 23 patients with antibiotic-associated dysbacteriosis and diarrhoea syndrome,
probiotics (manufactured by Kendy Pharma) were prescribed to 20 patients. An effect was reported in
17 patients.
CONCLUSIONS:
The above data convincingly demonstrate the effectiveness of probiotic products manufactured by
Kendy Pharma in cases of:
1. IBS.
2. Dysbacteriosis.
3. Post-antibiotic diarrhoea.
4. Probiotics manufactured by Kendy Pharma are reliable products. There have been no reports of any
adverse effects that could be associated with the intake of this type of probiotics.
Dr Vasil Rankov
Tsar Boris III National Integrated
Transport Hospital, Sofia, Bulgaria.
Lactoflor BioPlus is a proprietary probiotic combination containing only natural ingredients, including two unique strains: Lactobacilus bulgaricus and Streptococcus thermophilus. The fibers (inulin) added to the combination of Lactoflor BioPlus cleanse the body and support digestive processes, as well as the activity of beneficial bacteria.
Lactoflor BioPlus is particularly appropriate in a number of gastroenterological and hepatological pathologies observed in patients referred to our clinic. Lactoflor BioPlus is also applicable in patients after chemotherapy, radiation therapy and post-operative recovery.
The most common health cases include:
• Inflammatory disease of the lower gastrointestinal tract, with various pathophysiologies, such as
IBD, Crohn's disease, ulcerative colitis, and irritable bowel syndrome.
• Bacterial diarrhoea.
• Adjunctive therapy for Helicobacter pylori eradication.
• Dysbacteriosis.
• Lactase deficiency.
Lactoflor BioPlus should be taken 1 to 3 months, depending on the patient’s condition and disorder.
The combination of lactic acid bacteria and fibers improves and conditions the functioning of the stomach, small intestines, and colon. It also improves peristalsis and leads to normalising the functional condition of the gastrointestinal tract.
Lactoflor BioPlus can be administered (at physician’s discretion) in post-operative periods for quicker recovery of the functioning of the small intestines and colon, which results in more rapid recovery and reduces post-operative complications.
Efficiency of Lactoflor BioPlus
Nutritional value:
• Increases the body’s absorption of proteins, fats, and P, Ca, Fe.
• Enhances stability of vitamins В1, В2, В12.
• Stimulates release of digestive juices.
• Stimulates growth.
Health benefits:
• Regulates the function of the gastrointestinal tract.
• Strengthens the body’s resistance against contagious diseases.
• Mitigates milk sugar intolerance.
• Reduces amount of cholesterol and ammonia in the blood.
• Suppresses development of harmful organisms in the gastrointestinal tract.
• Anti-tumour effect.
• Increases life expectancy.
Dr K. Petrov
Clinic for Metabolic and Endocrine Diseases
and Dietology, Tsaritsa Yoanna ISUL University Hospital, Medical University, Sofia, Bulgaria.
The main properties of live organisms include feeding, breathing, movement, and reproduction, strongly influenced by technology and industrialisation. Those that are most affected include such high-risk groups as premature babies, infants, and children. Feeding and nutrition are among the first and most important interactions of the body with its environment.
The Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics (October 2001) defined probiotics as ‘live microorganisms which, when administered in adequate amounts, confer a health benefit on the [human] host’ (1). Experts’ consensus on this definition was based on the increasing number of scientific reports of health professionals, indicating that food with added live probiotics has beneficial effects on human health—in particular, live probiotics added to milk products have beneficial health effects on children and other high-risk populations.
Data resulting from scientific work have suggested that probiotics play an important role in immunological, digestive and respiratory functions, and could have a significant effect on the alleviation of infectious disease in children. Evidence in the research of health professionals prior to 2001 provoked more comprehensive studies of the effects of probiotics—studies which continue in order for data to be extrapulated to the entire population and separate high-risk groups. The most substantial research development was observed in the field of gastroenterology, with the effects of probiotics on the function of the GIT, the management of chronic GIT disease, and the function of the immune system mediated in the GIT. This research resulted in the creation of the guidelines of the World Gastroenterology Organisation in May 2008 (updated with current data in October 2011). The section entitled Probiotics, Prebiotics, and Evidence—the Global Picture (editions of the 2008/2011 guidelines) presents evidence concerning the genera, species, effects, number of references, and evidence level.
Lactoflor Kids is a synbiotic mixture which contains a prebiotic component
(oligofructose) and seven probiotic types of bacteria. Four of these types (L. helveticus, L.
acidophilus, L. bulgaricus, Str. thermophilus) belong to the genus of lactic acid bacteria (LAB),
and the other three (B. bifidum, B. infantis, B. longum) belong to the Bifidobacterium genus, which
also produce lactic acid.
The concept in developing the Lactoflor Kids combination is based on providing an adequate amount
of bacterial cells of these seven probiotic species, which have their own characteristic health
benefits and presence in the intestinal microbiota in children, as well as the prebiotic
oligofructose. (Oligofructose is a natural nutrient which is not catabolised by enzyme systems of
the human body but is catabolised by the enzyme systems of these seven probiotic species through
the production of lactic acid and fermentation. This process reduces PH in the intestines and
protects against contamination from potentially pathogenic bacteria.)
Oligofructose is a nutrient that can be absorbed by these seven probiotic species. This nutrient
aids in the increase of the number of probiotic bacterial cells, thereby potentiating the
predictable beneficial effects. Table 1 (below) shows the effects studied in various clinical
conditions in children, the number of references, evidence level, and recommended daily dose for
each probiotic species contained in Lactoflor Kids, including probiotic combinations. The order of
probiotics presented below does not favour any of the species contained in Lactoflor Kids. The data
in Table 1 (below) are based on the 2008/2011 guidelines of the World Gastroenterology
Organisation.
Probiotic/Effect studied | Number of references | Evidence level | Recommended daily dose | |
L. helveticus | ||||
L. acidophilus | L. acidophilus + B. infantis (Infloran strains) Treatment of acute infectious diarrhoea. |
2 | 109 CFU, three times daily | |
L. acidophilus + B. infantis Prevention of necrotizing enterocolitis in prematurely born babies. |
24 | 1b | 108 CFU, twice daily | |
B. bifidum NCDO 1453, L. acidophilus NCDO 1748 Prevention of necrotizing enterocolitis in prematurely born babies |
23 | 1b | 109 CFU, twice daily | |
L. bulgaricus | ||||
Str. thermophilus | B. lactis Bb12 + S. thermophilus Prevention of antibiotic-associated diarrhoea. |
8 | 1b | 107 + 106 CFU/g as per a formula |
B. lactis BB12 + S. thermophilus Prevention of nosocomial infectious diarrhoea. |
12 | 1b | 108 + 107 CFU/g as per a formula | |
B. infantis, S. thermophilus, and B. bifidum Prevention of necrotizing enterocolitis in prematurely born babies. |
23 | 1b | 109 CFU of each type, once daily | |
B. bifidum | B. infantis, S. thermophilus, and B. bifidum Prevention of necrotizing enterocolitis in prematurely born babies. |
23 | 1b | 109 CFU of each type, once daily |
B. bifidum NCDO 1453, L. acidophilus NCDO 1748 Prevention of necrotizing enterocolitis in prematurely born babies. |
23 | 1b | 109CFU of each type, twice daily | |
B. infantis, B. bifidum, S. thermophilus Prevention of necrotizing enterocolitis in prematurely born babies. |
25 | 1b | 109 CFU of each type, once daily | |
B. infantis | L. acidophilus + B. infantis (Infloran strains) Treatment of acute infectious diarrhoea. |
2 | 109 CFU of each type, three times | |
B. infantis, S. thermophilus, and B. bifidum Prevention of necrotizing enterocolitis in prematurely born babies. |
21 | 0.35 x 109CFU of each type, once daily | ||
L. acidophilus + B. infantis (Infloran strains) Prevention of necrotizing enterocolitis in prematurely born babies. |
24 | 1b | 109 CFU of each type, twice daily | |
B. infantis, B. bifidum, S. thermophilus Prevention of necrotizing enterocolitis in prematurely born babies. |
25 | 1b | 109 CFU of each type, once daily | |
B. longum |
Lactoflor Kids is a reliable synbiotic with a predictable beneficial effect on preserving children’s health in:
- • Treatment of acute infectious diarrhoea.
- • Prevention and treatment of antibiotic-associated diarrhoea.
- • Prevention and treatment of nosocomial infectious diarrhoea.
- • Prevention of necrotizing enterocolitis in prematurely born babies.
Health benefits can also be expected in:
- • Stomach bloating and gas.
- • Colic
- • Weakened immunity with seasonal changes.
- • During travel.
Dose and use recommended by the manufacturer:
Dilute one sachet in lukewarm water, milk, or juice. Take as follows:
- • For children 6 months to 2 years old: 1 sachet daily with meals.
- • For children 2 to 12 years old: 1 sachet twice daily with meals.


LACTOFLOR UROBIOTIC+
Probiotic blend with Ursolia® for prevention of urinary tract infections.
Suitable for prophylaxis and prevention of recurrent urinary tract infections.
A synergetic combination of well-researched herbal extracts (Ursolia® containing an extract of Salvia officinalis, and Exocyan® containing cranberry extract), D-mannose, and probiotic blend.
OTHER PRODUCTS
Lactoflor offers a full range of combined synbiotic products (prebiotics and probiotics) that contain selected strains of lactic acid bacteria, including Lactobacillus delbrueckii ssp. bulgaricus (Lactobacillus bulgaricus) and Streptococcus thermophilus, Lactobacillus acidophilus and Bifidobacterium ssp. Lactoflor is available in chewable tablets, capsules, or soluble sachets for children.








Lactoflor Kids
Specifically for Babies and Children - for Healthy Bellies and Strong Immunity
Lactoflor Kids contains seven strains of lactic acid bacteria, as well as fibers, developed especially for babies and young children—strains which help boost children’s immune protection and digestive system.
Lactoflor Kids alleviates symptoms of lactose intolerance and helps prevent and stop diarrhea symptoms.
Contains: 10 sachets per package
Read more
Lactoflor BioPlus Chewable tablets
Supports Dental Hygiene
Lactoflor BioPlus Chewable tablets are a special probiotic combination containing three strains of probiotics, prebiotics (inulin), and fibers. It comes in caramel flavour, yet sugar-free and free of artificial sweeteners or flavours. Lactoflor BioPlus Chewable tablets alleviate gum inflammation and prevents the formation of dental plaque by fighting harmful bacteria in the oral cavity.
Contains: 20 chewable tablets per package
Read more
Lactoflor BioPlus Capsules
Daily Care for Gastrointestinal Balance and Immune System Support
In addition to a combination of four unique types of lactic acid bacteria (Lactobacillus bulgaricus, Lactobacillus acidophilus, Streptococcus thermophilus, and Bifidobacterium sp.), Lactoflor BioPlus also contains fibers (inulin) which cleanse the body and support digestive processes, as well as the function of good bacteria.
Contains: 60 capsules per package
Read more
Lactoflor ProBiotic
For Better Health, Energy, and Resilience against Infection
Contains only natural ingredients and includes four unique types of lactic acid bacteria: Lactobacillus bulgaricus, Lactobacillus acidophilus, Streptococcus thermophilus, and Bifidobacterium sp.
Supports the functioning of gastric and intestinal flora impaired by intestinal infections and antibiotic treatment and improves the immune system.
Contains: 90 capsules per package
Read more
LACTOFLOR ENTERIC ECOL
An Effective Solution against Diarrhoea
Lactoflor Enteric Ecol is a probiotic product containing Saccharomyces boulardii (microorganisms which stops diarrhea in a natural way), as well as lactic acid bacteria (which restore the functions of intestinal flora).
Contains: 10 capsules/10 sachets
Read more